New Clinical Trial for Alveolar Soft Part Sarcoma in the United Kingdom: CASPS – A Phase II Trial of Cediranib

Dear ASPS Community,

We are very happy to report the opening of another clinical trial for ASPS patients in the United Kingdom. This new clinical trial is a phase II trial of Cediranib. Every trial brings with it the hope for cure!

ASPS patients who are trying Cediranib are sharing their experience on iCureASPS Forum. I would encourage everyone to click here and read comments and discussions of those patients. Please use our website, read and study well! Share information and communicate.

Best Wishes to everyone and thank you very much Dr. Judson and all who are working with you for taking the lead on this clinical trial.

Yosef Landesman, Ph.D.

President & Cancer Research Director



CASPS – A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma

Sponsored by: The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust

Information provided by: The Institute of Cancer Research – Clinical Trials and Statistics Unit Identifier: NCT01337401

Cediranib (AZD2171) is a new, unlicensed drug that has been studied in the laboratory and clinic, and researchers think it could slow the spread of ASPS. CASPS is a small clinical trial investigating cediranib in the treatment of ASPS, which is currently open to recruitment in the UK. Further information on CASPS and a list of hospitals involved in the trial can be found at:

Objective: The aim of this study is to see if cediranib (AZD2171) can help people with alveolar soft part sarcoma.

Eligibility: Individuals 16 years of age and older who have been diagnosed with alveolar soft part sarcoma. Please note that other eligibility criteria do apply – for further details please go to:

Contact: Professor Ian Judson,

Locations: United Kingdom